April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Attenuation of Iodine-125 Radiation With Vitreous Substitutes in the Treatment of Uveal Melanoma
Author Affiliations & Notes
  • S. C. Oliver
    Ophthalmology, University of Colorado Denver, Aurora, Colorado
  • M. Y. Leu
    Radiation Oncology, UCLA, Los Angeles, California
  • S. P. Lee
    Radiation Oncology, UCLA, Los Angeles, California
  • T. A. McCannel
    Ophthalmology, Jules Stein Eye Institute UCLA, Los Angeles, California
  • Footnotes
    Commercial Relationships  S.C. Oliver, Patent 61/143,310, P; M.Y. Leu, 61/143,310, P; S.P. Lee, None; T.A. McCannel, 61/143,310, P.
  • Footnotes
    Support  The project was supported by unrestricted grants from Research to Prevent Blindness, Inc., the George E. and Ruth Moss Trust and the Frederic G. Rappaport Fellowship Award to Scott C. N. Oliver, MD
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5146. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. C. Oliver, M. Y. Leu, S. P. Lee, T. A. McCannel; Attenuation of Iodine-125 Radiation With Vitreous Substitutes in the Treatment of Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5146.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To demonstrate attenuation of radiation from Iodine-125 (I-125) to intraocular structures using liquid vitreous substitutes.


Four candidate vitreous substitutes were tested for attenuation using empiric measurement and theoretic calculation. In vitro and ex vivo cadaveric dosimetry measurements were obtained with LiF thermoluminescent dosimeters (TLD) to demonstrate the attenuation effect of vitreous substitution during I-125 simulated plaque brachytherapy. Theoretical dosimetry calculations were based on Monte Carlo simulation.


In a cylindrical phantom at 17 mm depth, liquid vitreous substitutes, as compared to saline, showed significant reduction of radiation penetration (48% for silicone oil 1000 centistokes (cs) (polydimethylsiloxane), 47% for silicone oil 5000 cs (polydimethylsiloxane), 40% for heavy oil (perfluorohexyloctane / polydimethylsiloxane) and 35% for liquid perfluorocarbon (perfluoro-n-octane). Human cadaveric ex vivo measurements demonstrated a silicone oil 1000 cs to saline dose ratio of 35%, 52%, 55%, and 48% at arc lengths of 4.2, 7.6, 10.6, 22.3 and 28.6 mm from the plaque edge, respectively, along the surface of the globe. Monte Carlo simulation of a human globe projected attenuation as high as 57% using polydimethylsiloxane 1000 cs.


Intraocular vitreous substitutes including silicone oil, heavy oil, and perfluorocarbon liquid attenuate the radiation dose from I-125. Cadaveric ex vivo measurements and Monte Carlo simulation both demonstrate radiation attenuation using silicone oil 1000 cs at distances corresponding to vital ocular structures. Attenuation of radiation with silicone oil endotamponade in the treatment of uveal melanoma may significantly reduce radiation-induced injury to vital ocular structures.  

Keywords: melanoma • radiation therapy • vitreous substitutes 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.